188201-15-2

Usage

Uses

Used in Pharmaceutical Industry:
(S)-N-(1,2,3,4-Tetrahydro-2-naphthalenyl)butanamide is used as a potential therapeutic agent for the treatment of pain and inflammation due to its agonistic effects on cannabinoid receptors CB1 and CB2. Its analgesic and anti-inflammatory properties make it a promising candidate for the development of new medications to alleviate chronic and acute pain conditions.
Used in Neurological Disorders Treatment:
In the field of neurology, (S)-N-(1,2,3,4-Tetrahydro-2-naphthalenyl)butanamide is being explored as a potential treatment for various neurological disorders. Its agonistic action on cannabinoid receptors may help in managing symptoms associated with these conditions, such as spasticity, tremors, and cognitive impairments.
Used in Endocannabinoid System Modulation:
(S)-N-(1,2,3,4-Tetrahydro-2-naphthalenyl)butanamide is used as a modulator of the endocannabinoid system, which plays a crucial role in maintaining homeostasis and regulating various physiological processes. Its ability to interact with cannabinoid receptors CB1 and CB2 allows it to influence the system's activity, potentially leading to therapeutic benefits in conditions where the endocannabinoid system is dysregulated.
Used in Research and Development:
In the scientific community, (S)-N-(1,2,3,4-Tetrahydro-2-naphthalenyl)butanamide serves as a valuable research tool for studying the endocannabinoid system and its role in health and disease. Its structural similarity to anandamide and its agonistic effects on cannabinoid receptors make it an important compound for investigating the mechanisms of action and potential therapeutic applications of cannabinoids.

Upstream product

• 106-31-0 butanoic acid anhydride 
• 530-93-8 1,2,3,4-tetrahydronaphthalen-2-one 
• 1743-01-7 JGC 127 hydrochloride 

Downstream Products

• 35046-15-2 2-(N-Butyl-N-methyl)-amino-1,2,3,4-tetrahydro-naphthalene 

Relevant academic research and scientific papers

Ruthenium-Catalysed Enantioselective Hydrogenation of Trisubstituted Enamides Derived from 2-Tetralone and 3-Chromanone: Influence of Substitution on the Amide Arm and the Aromatic Ring

Cyclic enamides were prepared in one step from tetralone and chromanone derivatives and primary amides under acidic conditions. The enantio-selective hydrogenation of these enamides bearing an endocyclic trisubstituted carbon-carbon double bond was perfor

2-Amido-8-methoxytetralins: A Series of Nonindolic Melatonin-like Agents

A series of unsubstituted and methoxy-substituted 2-amidotetralins (4a-q) was prepared and evaluated for their ability to complete for 2-iodomelatonin binding to chicken retinal membranes and for their potency to inhibit the calcium-dependent release of dopamine from rabbit retina.The lead compound, 2-acetamido-8-methoxytetralin (4j), showed a moderate affinity (Ki = 46 nM) and potency (IC50 = 1.4 nM) at the melatonin receptor.The structural requirements necessary for optimal agonistic activity at the melatonin receptor are as follows.First, the amido group, which should have a small, nonbranched alkyl group, is essential for affinity, and second, the methoxy substituent at the 8-position of the 2-amidotetralin ring is essential for optimal agonistic activity at the melatonin receptor.We concluded that this series of unsubstituted and methoxy-substituted 2-amidotetralins constitutes a class of nonindolic melatonin-like agents that can be used as pharmacological tools to further characterize melatonin receptors and to elucidate the mode of action of melatonin.

SUBSTITUTED 2-AMIDOTETRALINS AS MELATONIN AGONISTS AND ANTAGONISTS

The present invention relates generally to compounds having melatonin receptor activities and in particular to substituted 2-amidotetralin derivatives; to pharmaceutical preparations comprising such compounds; and to methods for using these compounds as t

SUBSTITUTED 2-AMIDOTETRALINS AS MELATONIN AGONISTS AND ANTAGONISTS

The present invention relates generally to compounds having melatonin receptor activities and in particular to substituted 2-amidotetralin derivatives; to pharmaceutical preparations comprising such compounds; and to methods for using these compounds as t